Immunovant Planning Pivotal Trial of IMVT-1401

Immunovant Planning Pivotal Trial of IMVT-1401

295714

Immunovant Planning Pivotal Trial of IMVT-1401

Following a review of available clinical data, Immunovant has announced plans to resume clinical testing of the investigational medication IMVT-1401 in myasthenia gravis (MG) and other autoimmune conditions. Following discussions with regulatory agencies, the company is planning to launch a potentially pivotal trial of IMVT-1401 in MG, and to resume a Phase 2a study (NCT04253236) of the investigational medication in warm autoimmune hemolytic anemia, an autoimmune disease in which the body’s immune system wrongly attacks…

You must be logged in to read/download the full post.